Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer

Trial Details

NCT ID
NCT06344156
Phase
PHASE1
Sponsor
Sichuan University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Age ≥18 years and age ≤75 years.
  • ECOG score 0-1.
  • Patients with histologically confirmed pancreatic ductal adenocarcinoma, R0 resection, stage I-III, not receiving neoadjuvant therapy.
  • Adequate bone marrow and organ function:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →